MedTrace Logo

PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term Therapy

NCT01519856 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 908

Last updated 2016-01-29

No results posted yet for this study

Summary

Non-Ergot Dopamine agonists are meanwhile the drugs of first-choice in the treatment of Parkinson's disease. The receptor profile of the non-ergot dopamine-agonist piribedil is unique. In addition to agonistic effects on dopaminergic D2- and D3-receptors piribedil has adrenergic alpha-2A- and alpha-2C-receptors antagonisic properties. There is evidence from the literature that the antagonistic properties of piribedil are correlated with an improvement of cognitive function and vigilance parameters in parkinson's disease. The aim of the present non-interventional study is to investigate the safety and efficacy of piribedil during long-term therapy of patients with M. Parkinson under consideration of cognitive functions and quality of life.

Conditions

Interventions

DRUG

piribedil (Clarium)

oral tablets, 50 mg

Sponsors & Collaborators

  • Desitin Arzneimittel GmbH

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2014-12-31
Completion
2015-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01519856 on ClinicalTrials.gov